Literature DB >> 22650254

P53 mdm2 inhibitors.

Kareem Khoury1, Alex Dömling.   

Abstract

The protein-protein interaction (PPI) between p53 and its negative regulator MDM2 comprises one of the most important and intensely studied PPI's involved in preventing the initiation of cancer. The interaction between p53 and MDM2 is conformation-based and is tightly regulated on multiple levels. Due to the Angstrom level structural insight there is a reasonable understanding of the structural requirements needed for a molecule to bind to MDM2 and successfully inhibit the p53/MDM2 interaction. The current review summarizes the binding characteristics of the different disclosed small molecules for inhibition of MDM2 with a co-crystal structure. Synthetic access to these compounds as well as their derivatives are described in detail.

Entities:  

Mesh：

Substances：

Year:  2012        PMID： 22650254      PMCID： PMC3719986          DOI： 10.2174/138161212802651580

Source DB:  PubMed          Journal:  Curr Pharm Des        ISSN： 1381-6128            Impact factor:   3.116


  35 in total

1.  T antigen is bound to a host protein in SV40-transformed cells.

Authors:  D P Lane; L V Crawford
Journal:  Nature       Date:  1979-03-15       Impact factor: 49.962

2.  Exhaustive fluorine scanning toward potent p53-Mdm2 antagonists.

Authors:  Yijun Huang; Siglinde Wolf; David Koes; Grzegorz M Popowicz; Carlos J Camacho; Tad A Holak; Alexander Dömling
Journal:  ChemMedChem       Date:  2011-09-27       Impact factor: 3.466

3.  Benzodiazepinedione inhibitors of the Hdm2:p53 complex suppress human tumor cell proliferation in vitro and sensitize tumors to doxorubicin in vivo.

Authors:  Holly K Koblish; Shuyuan Zhao; Carol F Franks; Robert R Donatelli; Rose M Tominovich; Louis V LaFrance; Kristi A Leonard; Joan M Gushue; Daniel J Parks; Raul R Calvo; Karen L Milkiewicz; Juan José Marugán; Pierre Raboisson; Maxwell D Cummings; Bruce L Grasberger; Dana L Johnson; Tianbao Lu; Christopher J Molloy; Anna C Maroney
Journal:  Mol Cancer Ther       Date:  2006-01       Impact factor: 6.261

4.  Structure of the MDM2 oncoprotein bound to the p53 tumor suppressor transactivation domain.

Authors:  P H Kussie; S Gorina; V Marechal; B Elenbaas; J Moreau; A J Levine; N P Pavletich
Journal:  Science       Date:  1996-11-08       Impact factor: 47.728

5.  Robust generation of lead compounds for protein-protein interactions by computational and MCR chemistry: p53/Hdm2 antagonists.

Authors:  Anna Czarna; Barbara Beck; Stuti Srivastava; Grzegorz M Popowicz; Siglinde Wolf; Yijun Huang; Michal Bista; Tad A Holak; Alexander Dömling
Journal:  Angew Chem Int Ed Engl       Date:  2010-07-19       Impact factor: 15.336

6.  Immunochemical analysis of the interaction of p53 with MDM2;--fine mapping of the MDM2 binding site on p53 using synthetic peptides.

Authors:  S M Picksley; B Vojtesek; A Sparks; D P Lane
Journal:  Oncogene       Date:  1994-09       Impact factor: 9.867

Review 7.  Substituted 1,4-benzodiazepine-2,5-diones as alpha-helix mimetic antagonists of the HDM2-p53 protein-protein interaction.

Authors:  Maxwell D Cummings; Carsten Schubert; Daniel J Parks; Raul R Calvo; Louis V LaFrance; Jennifer Lattanze; Karen L Milkiewicz; Tianbao Lu
Journal:  Chem Biol Drug Des       Date:  2006-03       Impact factor: 2.817

Review 8.  Targeting Mdm2 and Mdmx in cancer therapy: better living through medicinal chemistry?

Authors:  Mark Wade; Geoffrey M Wahl
Journal:  Mol Cancer Res       Date:  2009-01       Impact factor: 5.852

9.  Reactivation of p53 by a specific MDM2 antagonist (MI-43) leads to p21-mediated cell cycle arrest and selective cell death in colon cancer.

Authors:  Sanjeev Shangary; Ke Ding; Su Qiu; Zaneta Nikolovska-Coleska; Joshua A Bauer; Meilan Liu; Guoping Wang; Yipin Lu; Donna McEachern; Denzil Bernard; Carol R Bradford; Thomas E Carey; Shaomeng Wang
Journal:  Mol Cancer Ther       Date:  2008-06       Impact factor: 6.261

Review 10.  Awakening guardian angels: drugging the p53 pathway.

Authors:  Christopher J Brown; Sonia Lain; Chandra S Verma; Alan R Fersht; David P Lane
Journal:  Nat Rev Cancer       Date:  2009-12       Impact factor: 60.716
View more
  17 in total

1.  2P2I HUNTER: a tool for filtering orthosteric protein-protein interaction modulators via a dedicated support vector machine.

Authors:  Véronique Hamon; Raphael Bourgeas; Pierre Ducrot; Isabelle Theret; Laura Xuereb; Marie Jeanne Basse; Jean Michel Brunel; Sebastien Combes; Xavier Morelli; Philippe Roche
Journal:  J R Soc Interface       Date:  2013-11-06       Impact factor: 4.118

2.  Emerging therapies targeting the ubiquitin proteasome system in cancer.

Authors:  Nathaniel M Weathington; Rama K Mallampalli
Journal:  J Clin Invest       Date:  2014-01-02       Impact factor: 14.808

Review 3.  Anticancer Effects of Constituents of Herbs Targeting Osteosarcoma.

Authors:  Qing-Hong Su; Xiao-Qun Xu; Jun-Fu Wang; Jun-Wen Luan; Xia Ren; Hai-Yan Huang; Si-Shan Bian
Journal:  Chin J Integr Med       Date:  2019-06-04       Impact factor: 1.978

4.  In vitro cytotoxicity and in vivo efficacy, pharmacokinetics, and metabolism of pyrazole-based small molecule inhibitors of Mdm2/4-p53 interaction.

Authors:  Susan M Christner; Dana M Clausen; Jan H Beumer; Robert A Parise; Jianxia Guo; Yijun Huang; Alexander S Dömling; Julie L Eiseman
Journal:  Cancer Chemother Pharmacol       Date:  2015-06-07       Impact factor: 3.333

Review 5.  Therapeutic opportunities in cancer therapy: targeting the p53-MDM2/MDMX interactions.

Authors:  Murali Munisamy; Nayonika Mukherjee; Levin Thomas; Amy Trinh Pham; Arash Shakeri; Yusheng Zhao; Jill Kolesar; Praveen P N Rao; Vivek M Rangnekar; Mahadev Rao
Journal:  Am J Cancer Res       Date:  2021-12-15       Impact factor: 6.166

Review 6.  Functional roles of E3 ubiquitin ligases in prostate cancer.

Authors:  Yiting Zhao; Jinyun Li; Jun Chen; Meng Ye; Xiaofeng Jin
Journal:  J Mol Med (Berl)       Date:  2022-07-11       Impact factor: 5.606

7.  Dinuclear platinum complexes containing planar aromatic ligands to enhance stacking interactions with proteins.

Authors:  Erin S F Ma; A Gerard Daniel; Nicholas P Farrell
Journal:  ChemMedChem       Date:  2014-05-06       Impact factor: 3.466

Review 8.  Targeting ubiquitination for cancer therapies.

Authors:  John Kenneth Morrow; Hui-Kuan Lin; Shao-Cong Sun; Shuxing Zhang
Journal:  Future Med Chem       Date:  2015-12-02       Impact factor: 3.808

9.  Nanoscale Synaptic Membrane Mimetic Allows Unbiased High Throughput Screen That Targets Binding Sites for Alzheimer's-Associated Aβ Oligomers.

Authors:  Kyle C Wilcox; Matthew R Marunde; Aditi Das; Pauline T Velasco; Benjamin D Kuhns; Michael T Marty; Haoming Jiang; Chi-Hao Luan; Stephen G Sligar; William L Klein
Journal:  PLoS One       Date:  2015-04-30       Impact factor: 3.240

10.  Energetic Landscape of MDM2-p53 Interactions by Computational Mutagenesis of the MDM2-p53 Interaction.

Authors:  Kelly M Thayer; George A Beyer
Journal:  PLoS One       Date:  2016-03-18       Impact factor: 3.240
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.